Page 56 - 82_03

Arantxa Rodríguez Casado, Adolfo Toledano-Díaz, Adolfo Toledano
Metab 2015;26:538-50.
10. Nguyen JC, Killcross AS, Jenkins TA. Obesity and
cognitive decline: role of inflammation and vascular
changes. Front Neurosci 2014;8:375.
11. Toda N, Ayajiki K, Okamura T. Obesity-induced
cerebral hypoperfusion derived from endothelial
dysfunction: one of the risk factors for Alzheimer's
disease. Curr Alzheimer Res 2014;11:733-44.
12. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013:
A decade of body mass index, Alzheimer's disease,
and dementia. J Alzheimer’s Dis 2015;43:739-55.
13. Meng XF, Yu JT, Wang HF, Tan MS, Wang C, Tan
CC, Tan L. Midlife vascular risk factors and the risk 27. Olmos-Alonso A, Schetters ST, Sri S, Askew K,
of Alzheimer's disease: a systematic review and meta-
analysis. J Alzheimers Dis 2014;42:1295-310.
14. Hildreth KL, Van Pelt RE, Schwartz RS. Obesity,
insulin resistance, and Alzheimer's disease. Obesity
(Silver Spring) 2012;20:1549-57.
15. Nuzzo D, Picone P, Baldassano S, Caruana L, Messina
E, Marino Gammazza A, Cappello F, Mulè F, Di
Carlo M. Insulin resistance as common molecular
denominator linking obesity to Alzheimer's Disease.
Curr Alzheimer Res 2015;12:723-35.
16. Ferreira ST, Clarke JR, Bomfim TR, DeFelice FG.
Inflammation, defective insulin signaling, and
neuronal dysfunction in Alzheimer's disease.
Alzheimers Dement 2014;10:S76-83.
17. De Felice FG, Lourenco MV, Ferreira ST. How does
brain insulin resistance develop in Alzheimer's
disease? Alzheimer’s Dement 2014;10:S26-32.
18. Shoelson SE, Lee J, Goldfine AB. Inflammation and
insulin resistance. J Clin Invest 2006;116:1793-801.
19. De la Monte SM, Tong M. Brain metabolic
dysfunction at the core of Alzheimer's disease.
Biochem Pharmacol 2014;88:548-59.
20. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP,
Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ,
Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA,
Bennett DA, Trojanowski JQ, Arnold SE.
Demonstrated brain insulin resistance in Alzheimer's
disease patients is associated with IGF-1 resistance,
IRS-1 dysregulation, and cognitive decline. J Clin
Invest 2012;122:1316-38.
21. Acharya NK, Levin EC, Clifford PM, Han M,
Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ,
Kosciuk MC, Nagele EP, Demarshall C, Freeman T,
Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele
RG. Diabetes and hypercholesterolemia increase
blood-brain barrier permeability and brain amyloid
deposition: beneficial effects of the LpPLA2 inhibitor
darapladib. J Alzheimer’s Dis 2013;35:179-98.
22. Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE,
Reijerkerk A, King-Robson J, Kay O, DeVries HE,
Hirst MC, Sharrack B, Baker D, Male DK, Michael
GJ, Romero IA. MicroRNA-155 negatively affects
blood-brain barrier function during
neuroinflammation. FASEB J 2014;28:2551-65.
314 @Real Academia Nacional de Farmacia. Spain
23. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A.
Possible implications of insulin resistance and glucose
metabolism in Alzheimer's disease pathogenesis. J
Cell Mol Med 2011;15:1807-21.
24. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H,
Morishita R. Increased blood-brain barrier
vulnerability to systemic inflammation in an
Alzheimer´s disease mouse model. Neurobiol Aging
2013;34:2064-70.
25. Hanisch UK. Microglia as a source and target of
cytokines. Glia 2002;40:140-55.
26. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M.
TREM2 binds to apolipoproteins, including APOE
and CLU/APOJ, and thereby facilitates uptake of Aß
by microglia. Neuron 2016;20;91:328-40.
Mancuso R, Vargas-Caballero M, Holscher C, Perry
VH, Gomez-Nicola D. Pharmacological targeting of
CSF1R inhibits microglial proliferation and prevents
the progression of Alzheimer's-like pathology. Brain
2016;139:891-907.
28. Gontier G, Lin K, Villeda SA. Fat chance for neural
stem cells in Alzheimer's disease. Cell Stem Cell
2015;17:373-4.
29. Hamilton LK, Dufresne M, Joppé SE, Petryszyn S,
Aumont A, Calon F, Barnabé-Heider F, Furtos A,
Parent M, Chaurand P, Fernandes KJ. Aberrant lipid
metabolism in the forebrain niche suppresses adult
neural stem cell proliferation in an animal model of
Alzheimer's disease. Cell Stem Cell 2015;17:397-411.
30. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR,
Tavares R, Xu XJ, Wands JR, De la Monte SM.
Impaired insulin and insulin-like growth factor
expression and signaling mechanisms in Alzheimer's
disease - is this type 3 diabetes? J Alzheimers Dis
2005;7:63-80.
31. Kroner Z. The relationship between Alzheimer's
disease and diabetes: Type 3 diabetes? Altern Med
Rev 2009;14:373-9.
32. Rivera E, Goldin A, Fulmer N, Tavares R, Wands JR,
de la Monte SM. Insulin and insulin-like growth factor
expression and function deteriorate with progression
of Alzheimer's disease: link to brain reductions in
acetylcholine. J Alzheimers Dis 2005;8:247-68.
33. De la Monte SM. Triangulated mal-signaling in
Alzheimer's disease: roles of neurotoxic ceramides,
ER stress, and insulin resistance reviewed. J
Alzheimer´s Dis 2012;30:S231-49.
34. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI,
Smith MA. Insulin-resistant brain state: the culprit in
sporadic Alzheimer's disease? Ageing Res Rev
2011;10:264-73.
35. Craft S. Insulin resistance syndrome and Alzheimer's
disease: age- and obesity-related effects on memory,
amyloid, and inflammation. Neurobiol Aging
2005;26:65-9.
36. Kuljis RO, Salkovic-Petrisic M. Dementia, diabetes,